OncLive TV

OncLive interviewed experts at the State of the Science Summits™ in February 2020 on common misconceptions in their respective fields.

Kavitha Ramchandran, MD, discusses considerations as patients with thoracic malignancies enter palliative care.

Samer K. Khaled, MD, discusses current recognition and treatment strategies for transplant-associated thrombotic microangiopathy.

Zofia Piotrowska, MD, MHS, discusses the patient populations eligible to receive osimertinib as treatment for lung cancer.

Praveen Ramakrishnan, MD, assistant professor, Department of Internal Medicine, UT Southwestern Medical Center, discusses updates in diffuse large B-cell lymphoma (DLBCL) that were presented at the 2019 ASH Annual Meeting.

Benjamin Heyman, MD, assistant clinical professor of medicine, University of California, San Diego, discusses the use of maintenance rituximab (Rituxan) in patients with follicular lymphoma.

Bradley McGregor, MD, discusses combination therapies with nivolumab, cabozantinib, and sunitinib in renal cell carcinoma.

Thomas Powles, MD, MBBS, MRCP, discusses the mission and goals for the Uromigos Twitter group.

Dimitrios Tzachanis, MD, PhD, discusses data with lisocabtagene maraleucel (liso-cel) in large B-cell lymphoma, as well as the differences between axicabtagene ciloleucel (axi-cel; Yescarta) and tisagenlecleucel (Kymriah).

Tracey Liebman, MD, discusses the use of digital surveillance in melanoma.

Alexander Leandros Lazarides, MD, discusses research regarding margin assessment in patients with sarcoma.

Young Kwang Chae, MD, MPH, MBA, discusses using crizotinib to treat MET-positive patients with non–small cell lung cancer.

Mark A. Schroeder, MD, discusses therapies currently available and being investigated to treat patients with graft-versus-host disease.

Karen L. Reckamp, MD, MS, discusses targeted therapy options for rare mutations in non–small cell lung cancer.

Aaron Goodman, MD, discusses factors that have contributed to the lack of treatment development in peripheral T-cell lymphoma.

Andrea Price, APN, discusses adding CAR T-cell therapy to the electronic medical record.

Monika Joshi, MD, discusses durvalumab (Imfinzi) and radiation therapy (DUART) in locally advanced urothelial cancer of the bladder.

Richard L. Shapiro, MD, discusses the surgical management of advanced-stage melanoma.

C. Parker Gibbs Jr, MD, discusses the lack of treatment options for patients with soft tissue and bone sarcomas.

James M. Rossetti, DO, discusses symptom management for patients with myeloproliferative neoplasms.

Naveen Pemmaraju, MD, discusses methods to address anemia in patients with myelodysplastic syndromes.

Marina Kremyanskaya, MD, PhD, discusses unmet needs in myelofibrosis.

Rana R. McKay, MD, discusses the results of a real-world analysis of radium-223 in patients with metastatic castration-resistant prostate cancer.

Neeraj Agarwal, MD, discusses the importance of developing biomarkers of response to the combination of cabozantinib and atezolizumab in patients with metastatic castration-resistant prostate cancer.

Julie N. Graff, MD, discusses the results of the phase II KEYNOTE-199 trial in metastatic castration-resistant prostate cancer.

William K. Oh, MD, discusses remaining challenges with the advancing treatments in prostate cancer.

Petros Grivas, MD, discusses comparisons between ATM and BRCA1/2 mutations in metastatic castration-resistant prostate cancer.

David S. Snyder, MD, discusses updates in treating patients with myelofibrosis who undergo transplant.

Andrew T. Kuykendall, MD, discusses the additionof fedratinib to the treatment paradigm in myelofibrosis.

Jacqueline S. Garcia, MD, discusses the tolerability of the combination of navitoclax plus ruxolitinib in patients with myelofibrosis.